Protein C, human (Ceprotin)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Human protein C

History of changes in EMA indication

  • 2001-07-16: Initial authorization as Ceprotin
  • Uncertain date: CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency.

Also known as

  • Brand name: Ceprotin